Acromioclavicular joint dysfunction is a painful condition that affects the shoulder joint. It occurs when the acromioclavicular (AC) joint, which is located between the acromion (the bony part of the shoulder blade) and the clavicle (collarbone), becomes inflamed or damaged. The condition can be caused by a variety of factors, including trauma, overuse, or degenerative diseases. Symptoms of acromioclavicular joint dysfunction include pain, swelling, and stiffness in the shoulder joint. It can also cause a loss of range of motion and difficulty performing everyday activities. Treatment for acromioclavicular joint dysfunction typically involves rest, physical therapy, medications, and sometimes surgery. However, these traditional treatments may not be effective in all cases. As a result, researchers and medical professionals are exploring innovative treatments for acromioclavicular joint dysfunction. This article will discuss some of the most promising new treatments for this condition. Viscosupplementation
Viscosupplementation is a new treatment for acromioclavicular joint dysfunction that involves injecting a gel-like substance into the joint. This gel-like substance is made up of hyaluronic acid, which is a naturally occurring substance found in the body that helps to lubricate and cushion the joint. The injection of this gel-like substance helps to reduce inflammation and pain, and improve joint mobility. Viscosupplementation has been found to be effective in reducing pain and improving joint mobility in patients with acromioclavicular joint dysfunction. In one study, patients who received viscosupplementation injections reported a significant reduction in pain and improved range of motion.
Platelet-Rich Plasma Therapy
Platelet-rich plasma (PRP) therapy is another new treatment for acromioclavicular joint dysfunction. This therapy involves extracting a sample of the patient’s blood and then separating out the platelets. The platelets are then injected into the affected joint. The platelets contain growth factors that can help to reduce inflammation and promote healing. Studies have found that PRP therapy is effective in reducing pain and improving joint mobility in patients with acromioclavicular joint dysfunction. In one study, patients who received PRP injections reported a significant reduction in pain and improved range of motion.
Extracorporeal Shock Wave Therapy
Extracorporeal shock wave therapy (ESWT) is a new treatment for acromioclavicular joint dysfunction that involves using high-energy sound waves to stimulate the affected joint. The shock waves help to reduce inflammation and promote healing. Studies have found that ESWT is effective in reducing pain and improving joint mobility in patients with acromioclavicular joint dysfunction. In one study, patients who received ESWT reported a significant reduction in pain and improved range of motion.
Stem Cell Therapy
Stem cell therapy is a promising new treatment for acromioclavicular joint dysfunction. This therapy involves extracting stem cells from the patient’s bone marrow or fat and then injecting them into the affected joint. The stem cells help to reduce inflammation and promote healing. Studies have found that stem cell therapy is effective in reducing pain and improving joint mobility in patients with acromioclavicular joint dysfunction. In one study, patients who received stem cell injections reported a significant reduction in pain and improved range of motion.
Conclusion
Acromioclavicular joint dysfunction is a painful condition that can cause a loss of range of motion and difficulty performing everyday activities. Traditional treatments for this condition, such as rest, physical therapy, medications, and sometimes surgery, may not be effective in all cases. As a result, researchers and medical professionals are exploring innovative treatments for acromioclavicular joint dysfunction. Some of the most promising new treatments for this condition include viscosupplementation, platelet-rich plasma therapy, extracorporeal shock wave therapy, and stem cell therapy. These treatments have been found to be effective in reducing pain and improving joint mobility in patients with acromioclavicular joint dysfunction.
1.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
2.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
3.
Recurrent UTIs impact eGFR in children with vesicoureteral reflux
4.
Month-Long Wait Times Caused by US Physician Shortage.
5.
Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.
1.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
2.
The Importance of Early Detection in Angiosarcoma: A Story of Survival
3.
Leukemia in Focus: Tools, Trials, and Therapy Strategies for Modern Medical Practice
4.
New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma
5.
Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation